Therapeutic nanoparticles for drug delivery in cancer

Kwangjae Cho, Xu Wang, Shuming Nie, Zhuo Chen, Dong M. Shin

Research output: Contribution to journalReview article

Abstract

Cancer nanotherapeutics are rapidly progressing and are being implemented to solve several limitations of conventional drug delivery systems such as nonspecific biodistribution and targeting, lack of water solubility, poor oral bioavailability, and low therapeutic indices. To improve the biodistribution of cancer drugs, nanoparticles have been designed for optimal size and surface characteristics to increase their circulation time in the bloodstream. They are also able to carry their loaded active drugs to cancer cells by selectively using the unique pathophysiology of tumors, such as their enhanced permeability and retention effect and the tumor microenvironment. In addition to this passive targeting mechanism, active targeting strategies using ligands or antibodies directed against selected tumor targets amplify the specificity of these therapeutic nanoparticles. Drug resistance, another obstacle that impedes the efficacy of both molecularly targeted and conventional chemotherapeutic agents, might also be overcome, or at least reduced, using nanoparticles. Nanoparticles have the ability to accumulate in cells without being recognized by P-glycoprotein, one of the main mediators of multidrug resistance, resulting in the increased intracellular concentration of drugs. Multifunctional and multiplex nanoparticles are now being actively investigated and are on the horizon as the next generation of nanoparticles, facilitating personalized and tailored cancer treatment.

Original languageEnglish (US)
Pages (from-to)1310-1316
Number of pages7
JournalClinical Cancer Research
Volume14
Issue number5
DOIs
StatePublished - Mar 1 2008

Fingerprint

Nanoparticles
Pharmaceutical Preparations
Neoplasms
Therapeutics
Tumor Microenvironment
Multiple Drug Resistance
P-Glycoprotein
Drug Delivery Systems
Drug Resistance
Solubility
Biological Availability
Permeability
Ligands
Water
Antibodies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Therapeutic nanoparticles for drug delivery in cancer. / Cho, Kwangjae; Wang, Xu; Nie, Shuming; Chen, Zhuo; Shin, Dong M.

In: Clinical Cancer Research, Vol. 14, No. 5, 01.03.2008, p. 1310-1316.

Research output: Contribution to journalReview article

Cho, Kwangjae ; Wang, Xu ; Nie, Shuming ; Chen, Zhuo ; Shin, Dong M. / Therapeutic nanoparticles for drug delivery in cancer. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 5. pp. 1310-1316.
@article{12e9ebfefbcc4b2b9d756d5e98a61efd,
title = "Therapeutic nanoparticles for drug delivery in cancer",
abstract = "Cancer nanotherapeutics are rapidly progressing and are being implemented to solve several limitations of conventional drug delivery systems such as nonspecific biodistribution and targeting, lack of water solubility, poor oral bioavailability, and low therapeutic indices. To improve the biodistribution of cancer drugs, nanoparticles have been designed for optimal size and surface characteristics to increase their circulation time in the bloodstream. They are also able to carry their loaded active drugs to cancer cells by selectively using the unique pathophysiology of tumors, such as their enhanced permeability and retention effect and the tumor microenvironment. In addition to this passive targeting mechanism, active targeting strategies using ligands or antibodies directed against selected tumor targets amplify the specificity of these therapeutic nanoparticles. Drug resistance, another obstacle that impedes the efficacy of both molecularly targeted and conventional chemotherapeutic agents, might also be overcome, or at least reduced, using nanoparticles. Nanoparticles have the ability to accumulate in cells without being recognized by P-glycoprotein, one of the main mediators of multidrug resistance, resulting in the increased intracellular concentration of drugs. Multifunctional and multiplex nanoparticles are now being actively investigated and are on the horizon as the next generation of nanoparticles, facilitating personalized and tailored cancer treatment.",
author = "Kwangjae Cho and Xu Wang and Shuming Nie and Zhuo Chen and Shin, {Dong M.}",
year = "2008",
month = "3",
day = "1",
doi = "10.1158/1078-0432.CCR-07-1441",
language = "English (US)",
volume = "14",
pages = "1310--1316",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Therapeutic nanoparticles for drug delivery in cancer

AU - Cho, Kwangjae

AU - Wang, Xu

AU - Nie, Shuming

AU - Chen, Zhuo

AU - Shin, Dong M.

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Cancer nanotherapeutics are rapidly progressing and are being implemented to solve several limitations of conventional drug delivery systems such as nonspecific biodistribution and targeting, lack of water solubility, poor oral bioavailability, and low therapeutic indices. To improve the biodistribution of cancer drugs, nanoparticles have been designed for optimal size and surface characteristics to increase their circulation time in the bloodstream. They are also able to carry their loaded active drugs to cancer cells by selectively using the unique pathophysiology of tumors, such as their enhanced permeability and retention effect and the tumor microenvironment. In addition to this passive targeting mechanism, active targeting strategies using ligands or antibodies directed against selected tumor targets amplify the specificity of these therapeutic nanoparticles. Drug resistance, another obstacle that impedes the efficacy of both molecularly targeted and conventional chemotherapeutic agents, might also be overcome, or at least reduced, using nanoparticles. Nanoparticles have the ability to accumulate in cells without being recognized by P-glycoprotein, one of the main mediators of multidrug resistance, resulting in the increased intracellular concentration of drugs. Multifunctional and multiplex nanoparticles are now being actively investigated and are on the horizon as the next generation of nanoparticles, facilitating personalized and tailored cancer treatment.

AB - Cancer nanotherapeutics are rapidly progressing and are being implemented to solve several limitations of conventional drug delivery systems such as nonspecific biodistribution and targeting, lack of water solubility, poor oral bioavailability, and low therapeutic indices. To improve the biodistribution of cancer drugs, nanoparticles have been designed for optimal size and surface characteristics to increase their circulation time in the bloodstream. They are also able to carry their loaded active drugs to cancer cells by selectively using the unique pathophysiology of tumors, such as their enhanced permeability and retention effect and the tumor microenvironment. In addition to this passive targeting mechanism, active targeting strategies using ligands or antibodies directed against selected tumor targets amplify the specificity of these therapeutic nanoparticles. Drug resistance, another obstacle that impedes the efficacy of both molecularly targeted and conventional chemotherapeutic agents, might also be overcome, or at least reduced, using nanoparticles. Nanoparticles have the ability to accumulate in cells without being recognized by P-glycoprotein, one of the main mediators of multidrug resistance, resulting in the increased intracellular concentration of drugs. Multifunctional and multiplex nanoparticles are now being actively investigated and are on the horizon as the next generation of nanoparticles, facilitating personalized and tailored cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=40949127319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40949127319&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-1441

DO - 10.1158/1078-0432.CCR-07-1441

M3 - Review article

C2 - 18316549

AN - SCOPUS:40949127319

VL - 14

SP - 1310

EP - 1316

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -